Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols

Protocols

EDRN investigators protocols. The following is a list of the EDRN protocols that have been captured and curated. Additional information will be added as it is available. Contact information is provided as part of the detail for each protocol.

Contents

Title Abstract Investigator
Biomarker Reference Sets for Cancers in Women The purpose of this study is to develop a standard reference set of specimens for use by investigators participating in the National Cancer Institutes Early ... Cramer, Daniel
Biomarkers and clinical parameters associated with Gleason score upgrading Thompson, Ian M.
Biomarkers for Prostate and Bladder Cancer CD26+ cancer cells and CD90+ tumor-associated stromal cells were sorted from tumor tissue. Dataset analysis with transcriptomes of CD26+ luminal, CD104+ basal, ... Liu, Alvin Y.
Biomarkers for early detection of pancreatic cancer Background: The clinical management of pancreatic cancer is severely hampered by the absence of effective screening tools. Methods: Sixty-seven biomarkers ... Lokshin, Anna
Biomarkers for the Early Detection of Pancreatic Cancer Killary, Ann M.
Biomarkers in Familial Multiple Myeloma Lynch, Henry
Biomarkers of Risk for Colorectal Neoplasia To explore biomarkers of risk of adenoma and adenoma recurrence Schoen, Robert E.
Biomarkers of Risk for Colorectal Neoplasia (Team Project #2) Investigators in the colon section of EDRN have a mutual interest in developing markers that would identify individuals at increased risk for colon neoplasia. ... Schoen, Robert E.
Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non- progressing cancers We hypothesize that our novel Biomarker Panel of Auto-antibodies can distinguish aggressive, symptom diagnosed lung cancer from non-aggressive, screen-detected ... Rom, William
Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non-progressing Cancer Distinguishing aggressive cancers from non-aggressive or non-progressing cancers is an issue of both clinical and public health importance particularly for ... Li, Christopher
Body Fluids as a Source of Diagnostic Biomarkers Semmes, John
Body Fluids as a Source of Diagnostic Biomarkers: Breast Semmes, John
Body Fluids as a Source of Diagnostic Biomarkers: Prostate Recent advances in high-throughput protein expression profiling of bodily fluids has generated great enthusiasm and hope for this approach as a potent ... Semmes, John
Breast Cancer: subgroups specific blood-biomarkers for early / predictive diagnosis and personalized treatment Breast-conserving lumpectomy followed by radiation therapy has been shown to be an alternative strategy, competitive to mastectomy, in preventing mortality ... Golubnitschaja, Prof. Dr. Olga
Breast Ductal Lavage Fluid Specimen Bank Trock, Bruce
Breast Ref Applicant: Abbott-Arkansas Medical Sciences (2013) We are evaluating whether detection of a tumor-specific N-linked glycosylation known as B 1,6 branched N-glycan present on the glycoprotein periostin in breast ... Abbott, Karen
Breast Ref Applicant: Anderson-Arizona (2014) The aims of the proposal are to evaluate this panel of 28 AAb biomarkers using the EDRN reference set. We propose to use RAPID ELISA containing each of these ... Anderson, Karen
Breast Ref Applicant: Chris Li (2014) Li, Christopher
Breast Ref Applicant: Chris Li-FHCRC (2014) Li, Christopher
Breast Ref Applicant: Mukherhjee-CanDiag (2014) Mukherhjee, Pinku
Breast Ref Applicant: Mukherjee 2014 Mukherhjee, Pinku
Breast Ref Set Applicant: Anu Mathew-Meso Scale (2012) Mathew, Anu
Breast Reference Set Applicant: Tuszynski-Temple (2012) Feng, Ziding
Breast Reference Set Applicant: Zangar-PNNL (2012) Feng, Ziding
Breast Reference Set Applicant:- Zangar-Pacific NW Nat'l Laboratory (2012) Feng, Ziding
Breast tissue array Chia, David
CLUE Studies: Evaluating Biomarkers of Carcinogenesis Helzlsouer, Kathy
Canary TMA This protocol describes a multi-center, retrospective, case-cohort tissue microarray (TMA) study to evaluate tissue biomarkers for their ability to predict ... Nelson, Peter S
Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients BACKGROUND: Carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC-Ag), and CYFRA 21-1 are the most useful markers for non-small cell lung ... Kulpa, Jan
Chemokine Prostate Cancer Biomarkers STUDY DESIGN 1. The need for pre-validation studies. Preliminary data from our laboratory demonstrates a potential utility for CXCL5 and CXCL12 as biomarkers ... Macoska, Jill
2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.